A number of other analysts have also recently weighed in on the stock. Morgan Stanley decreased their price target on shares of DexCom from $72.00 to $52.00 and set a neutral rating for the company in a research note on Friday, November 3rd. BidaskClub upgraded shares of DexCom from a buy rating to a strong-buy rating in a research note on Tuesday, December 12th. Northland Securities reiterated a sell rating and set a $40.00 price target on shares of DexCom in a research note on Tuesday, January 16th. Jefferies Group increased their price target on shares of DexCom from $58.00 to $70.00 and gave the stock a buy rating in a research note on Friday, December 22nd. Finally, BMO Capital Markets increased their price target on shares of DexCom to $74.00 and gave the stock an outperform rating in a research note on Tuesday, December 12th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of $65.97.
Shares of DexCom (NASDAQ DXCM) traded up $0.42 during trading hours on Wednesday, reaching $56.14. 1,835,100 shares of the company were exchanged, compared to its average volume of 1,262,705. The firm has a market cap of $4,842.24, a PE ratio of -95.15 and a beta of 0.21. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86. DexCom has a 12-month low of $42.62 and a 12-month high of $86.32.
In other news, EVP Richard Doubleday sold 1,638 shares of the firm’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $56.32, for a total value of $92,252.16. Following the completion of the sale, the executive vice president now owns 65,049 shares in the company, valued at approximately $3,663,559.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 6,000 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $58.85, for a total transaction of $353,100.00. The disclosure for this sale can be found here. Insiders sold a total of 34,153 shares of company stock valued at $1,953,327 in the last 90 days. Company insiders own 1.70% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in DXCM. American International Group Inc. acquired a new stake in shares of DexCom in the fourth quarter valued at about $116,000. Thompson Davis & CO. Inc. acquired a new stake in shares of DexCom in the fourth quarter valued at about $137,000. Zions Bancorporation lifted its stake in shares of DexCom by 36,222.2% in the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock valued at $160,000 after purchasing an additional 3,260 shares during the period. Toronto Dominion Bank lifted its stake in shares of DexCom by 251.0% in the third quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock valued at $178,000 after purchasing an additional 2,608 shares during the period. Finally, Marco Investment Management LLC acquired a new stake in shares of DexCom in the fourth quarter valued at about $201,000.
WARNING: “Oppenheimer Analysts Give DexCom (DXCM) a $67.00 Price Target” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3231057/oppenheimer-analysts-give-dexcom-dxcm-a-67-00-price-target.html.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.